




Corporate Presentation

August 2025



Injectables
Inhalation
Intranasal

Highly Purified
Peptide/Protein



Proprietary

Biosimilar
Interchangeable

Complex
Generic
Combination
Products

Forward Looking Statements

This presentation and the accompanying oral presentation contain forward-looking statements, of Amphastar Pharmaceuticals, Inc. ("Amphastar", "we", "our" and that are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including, but not limited to, information concerning our business plans and objectives, potential growth opportunities, product development, regulatory approvals, market potential, efficiencies, competitive position, and industry environment, among other statements.

All statements in this presentation and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of BAQSIMI® and Primatec MIST®, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, expansion of our headquarters, including quadrupling our production capacity and manufacturing capabilities, the resilience of our supply chain, our ability to expand our automation capabilities and integrate advanced technologies, our ability to create new jobs in the future, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at <http://ir.amphastar.com> and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this presentation or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

The forward-looking statements in this presentation speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur as forward-looking statements are inherently susceptible to uncertainty and changes in circumstances as with any projections or forecasts. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. Any forward-looking statements made by us in this presentation speak only as of the date of this presentation, and we undertake no obligation to update any forward-looking statements for any reason after the date of this presentation, except as required by law.

All third-party brand names and logos appearing in this presentation are trademarks or registered trademarks of their respective holders. Any such appearance does not necessarily imply any endorsement of the company.

Company Overview

Company Overview

One-
Stop

Dual
Strategies
Growth
Model

Three-H
Focus


- Fully Integrated Business Model, R&D, Manufacturing and Distribution

- Pipeline Development
- Strategic Acquisitions

- High Quality
- High Efficiency
- High Technology


Fully Integrated Business Model: One-Stop

- Extensive in-house product development capabilities
 - Technical Platforms
 - State-of-the-art instruments
 - Animal studies
 - Clinical research team
- Fully integrated back-end manufacturing capabilities
 - API and key materials
 - Device and key components
- Complete front-end integration
 - Marketing
 - Distribution



- Control over quality and compliance throughout the product development and manufacturing cycle

Dual-Strategies Growth Model




Three-H Focus

Amphastar's Management team operates the Company to:

- Insist on High Quality
- Emphasize High Efficiency and
- Rely on High Technology to Develop Pipelines

The 3-H focus results in high net income margin

| (\$Million or Specified) | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|------|------|------|-------|-------|-------|-------|
| Revenue, x | 295 | 322 | 350 | 438 | 499 | 644 | 732 |
| Net Income (GAAP) | -5.7 | 48.9 | 1.4 | 62.1 | 91.4 | 137.5 | 159.5 |
| Net Income, Adjusted, y | 10.4 | 17.8 | 31.6 | 68.0 | 103.2 | 175.7 | 200.8 |
| Net Income Margin, Adjusted, $=y/x, \%$ | 3.5% | 5.5% | 9.0% | 15.5% | 20.7% | 27.3% | 27.4% |




Leveraging Strategic Vision & Core Strengths



Pipeline Evolution

Amphastar's pipeline is projected to advance with a greater focus on proprietary and biosimilar products


2021 Pipeline




Projected 2026 Pipeline



Technical Platforms



Strategic Shift Toward Proprietary & Biosimilars Drugs





R&D and Pipeline

Focused on R&D Investment

- Strategic focus to make substantial R&D investments to expand our product portfolio
- Diverse pipeline development with flexibility and scalability for sourcing API, starting material, and research under our vertically –integrated platform
- Emphasis and investment in R&D differentiates us from our competitors as our focus is on the long-term growth of our company
- R&D from API, early stage, and clinical trials and from laboratory to scale-up

Self-funded R&D investment of approximately \$351 million in the recent 5 years



Pipeline – ANDAs and BLAs with Technical Barriers

| Generic Pipeline, 7 Candidates | | | | | |
|--------------------------------|------------------------|--|--|----------------|--|
| ANDA Type | Product Code | Current Stage | | *IQVIA Sales | |
| Injectable | AMP-002 | GDUFA 2Q 2023, No pending requests as of 8/06/25 | | +\$500 Million | |
| | AMP-015 (Teriparatide) | GDUFA 4Q 2025 | | +\$500 Million | |
| | AMP-018 (GLP-1) | CRL Received; Planned response 2H 2025 | | +\$400 Million | |
| Inhalation | AMP-007 | CRL Received; GDUFA 1H 2026 | | +\$1.5 Billion | |
| | AMP-017 | Planned filing 1H 2026 | | | |
| | AMP-023 | Development | | | |
| Biosimilar | AMP-028 | Development | | +\$2.0 Billion | |

Diabetes Portfolio

Commercialized

Glucagon Inj. Kit

BAQSIMI® Nasal Powder

GLP-1

AMP-018

GLP-1
ANDA

Interchangeable Insulin Pipeline

AMP-004

Insulin
Aspart

AMP-005

Recombinant
Human Insulin



AMP-025

Insulin
Degludec



- BAQSIMI®, the first and only FDA approved glucagon nasal powder
- The first FDA approved generic Glucagon injection kit
- GLP-1 ANDA filed
- Insulin Pipeline:
 - Covers the full spectrum of the insulin from rapid to long acting
 - AMP-004 BLA BsUFA 1Q 2026
 - \$4.5 Billion in IQVIA sales, ~70 million units of both pens and vials

Sales and Marketing

Sales and EPS Trend




Recent Quarter Trend: Sales & Adjusted EPS





Existing Products Provide Strong Base

New Launches have Supported Diversification of the Revenue Base



■ Enox. ■ Lidocaine ■ Naloxone ■ Insulin API
■ Vita K ■ Epi ■ Other Pharma



■ Enox. ■ Lidocaine ■ Naloxone ■ Insulin API
■ Vita K ■ Epi ■ Primatene MIST® ■ Glucagon
■ Baqsimi® ■ Other New Launches ■ All Other Pharma

Key Proprietary Products

BAQSIMI® Strategic Rationale: A Transformative Transaction for Amphastar



BAQSIMI® Patient Impact

Glucagon is underutilized:

The American Diabetes Association (ADA) recommends that patients at increased risk for Level 2 hypoglycemia be prescribed glucagon¹

Amphastar will focus on BAQSIMI® to better serve patients

Approximately 7 million people are treated with insulin and only about 0.85 million (~12%)² of these patients currently utilize glucagon

BAQSIMI® is currently a category leader for ease in patient use:

Simple nasal administration:

Currently the only non-injection glucagon approved by the FDA, passively absorbed in the nose, provide lower barrier for administration than injection

Ready-to-use with no reconstitution or priming required

Portability for Consumers:

Smaller product size than other glucagon products, and wider temperature storage range than other glucagon injection product.

¹American Diabetes Association. *Standards of Medical Care in Diabetes—2020*. *Diabetes Care*. 2020;43(suppl 1):S1-S212.

²Estimates based on IQVIA Annual TRx volume in 2024.

BAQSIMI® Forecast

■ Sales

- Projected to reach peak of \$250 million to \$275 million

■ Selling Expense


- Projected to be 15% of Baqsimi® sales
- Starting in January 2025: Collaboration with Mannkind to increase Baqsimi® sales footprint with their endocrinology focused sales force

■ Adjusted EPS⁽¹⁾

- Project \$2.00 to \$2.50 incremental adjusted EPS at peak


(1) Adjusted EPS is a non-GAAP financial measure. Reconciliation to the nearest GAAP measure is unavailable without unreasonable efforts. Refer to the section titled "Non-GAAP Financial Measures" for an explanation of non-GAAP financial measures.

BAQSIMI® Worldwide Annual Sales



Primatene MIST®

- Primatene MIST®, a proprietary and patent-protected over-the-counter epinephrine inhalation product
- Surpassed \$100mm sales target in 2024
- The only FDA approved asthma inhaler available OTC, launched Dec 2018
- US Adult asthma patients: 20 million per CDC⁽¹⁾
- Starting in January 2025: increase physician sampling program
- Development of proprietary Green⁽²⁾ propellant formulation with patent pending
- Forecasting high single-digit growth in 2025



1. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm

2. Low global warming potential

Highlights and Catalysts

Growth Drivers and Upcoming Milestones

Key Growth Drivers in 2025/2026

- **BAQSIMI®**
 - *Increased sales footprint*
- **Primatene MIST®**
 - *Advertising campaign*
 - *Increased physician sampling program*
- **Albuterol**
 - *Launched in August 2024*
- **Expected approvals**
 - *AMP-002 GDUFA 2Q 2023; No pending FDA requests*
 - *AMP-015 (Teriparatide) GDUFA 4Q 2025*
 - *AMP-007 GDUFA 1H 2026*

Milestones

Recent Filings

- **AMP-007 ANDA**
- **AMP-018 ANDA GLP-1**
- **AMP-004 BsUFA 1Q 2026**

Planned Filings in 2025/2026

- **REXTOVY™ Rx to OTC switch**
- **AMP-017 ANDA**